Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.
Also called NCT07146360
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 180 participants
- Sponsor
- Registry
-
NCT07146360
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Russia
- Registry status
- Completed
Technical summary
Registry record NCT07146360. Randomized; single masking; primary purpose treatment. Start 2014-05-25 (actual); primary completion 2017-11-21 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety Study of Proposed Biosimilar Product Reveliza vs Actilise in Patients With ST-segment Elevation Myocardial Infarction
- Condition
- Myocardial Infarction (MI)
- Intervention (Biological)
- Revelise (GENERIUM, Russia)
- Intervention (Biological)
- Actilyse® (Boehringer Ingelheim Pharma GmbH and Co.KG, Germany)
- Lead sponsor
- AO GENERIUM
Record details
- Record id
cardio:ct-nct07146360- Content hash
e03126f55a4a3a82af5f60cb1214a71aae27948af903957f34c1700fde1b2ca9